内源性大麻素系统在肝脏疾病中的作用的研究进展。
Recent advances in the understanding of the role of the endocannabinoid system in liver diseases.
机构信息
Department of Internal Medicine, Texas A&M Health Science Center College of Medicine, Temple, TX, USA.
出版信息
Dig Liver Dis. 2011 Mar;43(3):188-93. doi: 10.1016/j.dld.2010.08.010. Epub 2010 Oct 8.
Abstract
Endocannabinoids are ubiquitous signalling molecules that exert their effects through a number of specific cannabinoid receptors. Recent studies have indicated that this endocannabinoid system is involved in the pathophysiological processes associated with both acute and chronic liver diseases as well as in the complications that arise from these diseases such as hepatic encephalopathy and cardiac problems. Targeting this signalling system has been useful in ameliorating some of the symptoms and consequences in experimental models of these liver diseases. This review summarises the recent advances into our knowledge and understanding of endocannabinoids in liver diseases and highlights potential novel therapeutic strategies that may prove useful to treat these diseases.
摘要
内源性大麻素是普遍存在的信号分子，通过多种特定的大麻素受体发挥作用。最近的研究表明，该内源性大麻素系统参与了与急性和慢性肝病相关的病理生理过程，以及这些疾病引起的并发症，如肝性脑病和心脏问题。针对该信号系统在改善这些肝病的实验模型中的一些症状和后果方面是有用的。这篇综述总结了我们对内源性大麻素在肝脏疾病中的最新认识和理解，并强调了可能对治疗这些疾病有用的潜在新的治疗策略。
相似文献
1
Recent advances in the understanding of the role of the endocannabinoid system in liver diseases.内源性大麻素系统在肝脏疾病中的作用的研究进展。
Dig Liver Dis. 2011 Mar;43(3):188-93. doi: 10.1016/j.dld.2010.08.010. Epub 2010 Oct 8.
2
Endocannabinoids and liver disease. III. Endocannabinoid effects on immune cells: implications for inflammatory liver diseases.内源性大麻素与肝脏疾病。III. 内源性大麻素对免疫细胞的影响：对炎症性肝病的意义。
Am J Physiol Gastrointest Liver Physiol. 2008 Apr;294(4):G850-4. doi: 10.1152/ajpgi.00523.2007. Epub 2008 Jan 31.
3
Endocannabinoids in liver disease.内源性大麻素在肝脏疾病中的作用。
Hepatology. 2011 Jan;53(1):346-55. doi: 10.1002/hep.24077.
4
The endocannabinoid system in cholestasis.
Dig Liver Dis. 2011 Dec;43(12):1026-7. doi: 10.1016/j.dld.2011.05.005. Epub 2011 Aug 3.
5
Review article: the endocannabinoid system in liver disease, a potential therapeutic target.综述文章：肝脏疾病中的内源性大麻素系统，一个有潜力的治疗靶点。
Aliment Pharmacol Ther. 2014 Apr;39(8):790-801. doi: 10.1111/apt.12673. Epub 2014 Feb 24.
6
Endocannabinoids and liver disease. I. Endocannabinoids and their receptors in the liver.内源性大麻素与肝脏疾病。一、肝脏中的内源性大麻素及其受体。
Am J Physiol Gastrointest Liver Physiol. 2008 Jan;294(1):G9-G12. doi: 10.1152/ajpgi.00467.2007. Epub 2007 Nov 1.
7
Endocannabinoids in liver disease and hepatic encephalopathy.内源性大麻素与肝脏疾病和肝性脑病
Curr Pharm Des. 2008;14(23):2362-9. doi: 10.2174/138161208785740063.
8
Endocannabinoids signaling: Molecular mechanisms of liver regulation and diseases.内源性大麻素信号传导：肝脏调节和疾病的分子机制。
Front Biosci (Landmark Ed). 2016 Jun 1;21(7):1488-501. doi: 10.2741/4468.
9
Endocannabinoids as novel mediators of liver diseases.内源性大麻素作为肝脏疾病的新型介质
J Endocrinol Invest. 2006;29(3 Suppl):58-65.
10
Opposing actions of endocannabinoids on cholangiocarcinoma growth is via the differential activation of Notch signaling.内源性大麻素对胆管癌细胞生长的相反作用是通过 Notch 信号通路的差异激活。
Exp Cell Res. 2010 May 15;316(9):1465-78. doi: 10.1016/j.yexcr.2010.03.017. Epub 2010 Mar 25.
引用本文的文献
1
DAGLβ is the principal synthesizing enzyme of 2-AG and promotes aggressive phenotype of intrahepatic cholangiocarcinoma via AP-1/DAGLβ/miR4516 feedforward circuitry.DAGLβ 是 2-AG 的主要合成酶，通过 AP-1/DAGLβ/miR4516 正反馈回路促进肝内胆管癌的侵袭表型。
Am J Physiol Gastrointest Liver Physiol. 2023 Sep 1;325(3):G213-G229. doi: 10.1152/ajpgi.00243.2022. Epub 2023 Jun 27.
2
Cannabis for Rheumatic Disease Pain: a Review of Current Literature.大麻治疗风湿性疾病疼痛：当前文献综述。
Curr Rheumatol Rep. 2022 May;24(5):119-131. doi: 10.1007/s11926-022-01065-7. Epub 2022 Apr 29.
3
High omega arachidonic acid/docosahexaenoic acid ratio induces mitochondrial dysfunction and altered lipid metabolism in human hepatoma cells.高欧米伽花生四烯酸/二十二碳六烯酸比值会诱导人肝癌细胞的线粒体功能障碍并改变脂质代谢。
World J Hepatol. 2020 Mar 27;12(3):84-98. doi: 10.4254/wjh.v12.i3.84.
4
Preclinical and Clinical Assessment of Cannabinoids as Anti-Cancer Agents.大麻素作为抗癌剂的临床前和临床评估
Front Pharmacol. 2016 Oct 7;7:361. doi: 10.3389/fphar.2016.00361. eCollection 2016.
5
Exogenous hepatitis B virus envelope proteins induce endoplasmic reticulum stress: involvement of cannabinoid axis in liver cancer cells.外源性乙肝病毒包膜蛋白诱导内质网应激：大麻素轴在肝癌细胞中的作用
Oncotarget. 2016 Apr 12;7(15):20312-23. doi: 10.18632/oncotarget.7950.
6
Cannabinoid receptor signaling regulates liver development and metabolism.大麻素受体信号传导调节肝脏发育和代谢。
Development. 2016 Feb 15;143(4):609-22. doi: 10.1242/dev.121731.
7
Inhibiting CB1 receptors improves lipogenesis in an in vitro non-alcoholic fatty liver disease model.在体外非酒精性脂肪性肝病模型中，抑制CB1受体可改善脂肪生成。
Lipids Health Dis. 2014 Nov 18;13:173. doi: 10.1186/1476-511X-13-173.
8
Marijuana smoking does not accelerate progression of liver disease in HIV-hepatitis C coinfection: a longitudinal cohort analysis.大麻吸食不会加速 HIV-丙型肝炎合并感染患者的肝病进展：一项纵向队列分析。
Clin Infect Dis. 2013 Sep;57(5):663-70. doi: 10.1093/cid/cit378. Epub 2013 Jun 28.
9
Suppression of CB1 cannabinoid receptor by lentivirus mediated small interfering RNA ameliorates hepatic fibrosis in rats.慢病毒介导的小干扰 RNA 抑制 CB1 大麻素受体可改善大鼠肝纤维化。
PLoS One. 2012;7(12):e50850. doi: 10.1371/journal.pone.0050850. Epub 2012 Dec 12.
10
Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities.靶向内源性大麻素系统的大麻素受体激动剂：药理学策略和治疗可能性。
Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367(1607):3353-63. doi: 10.1098/rstb.2011.0381.
本文引用的文献
1
Opposing actions of endocannabinoids on cholangiocarcinoma growth is via the differential activation of Notch signaling.内源性大麻素对胆管癌细胞生长的相反作用是通过 Notch 信号通路的差异激活。
Exp Cell Res. 2010 May 15;316(9):1465-78. doi: 10.1016/j.yexcr.2010.03.017. Epub 2010 Mar 25.
2
Clinical implications of novel aspects of biliary pathophysiology.胆系生理学新方面的临床意义。
Dig Liver Dis. 2010 Apr;42(4):238-44. doi: 10.1016/j.dld.2010.01.005. Epub 2010 Feb 18.
3
The synthetic cannabinoid WIN 55,212-2 sensitizes hepatocellular carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by activating p8/CCAAT/enhancer binding protein homologous protein (CHOP)/death receptor 5 (DR5) axis.合成大麻素 WIN 55,212-2 通过激活 p8/CCAAT/增强子结合蛋白同源蛋白 (CHOP)/死亡受体 5 (DR5) 轴使肝癌细胞对肿瘤坏死因子相关凋亡诱导配体 (TRAIL) 诱导的细胞凋亡敏感。
Mol Pharmacol. 2010 May;77(5):854-63. doi: 10.1124/mol.109.062257. Epub 2010 Feb 16.
4
Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis.肝硬化患者的循环和肝脏内源性大麻素及内源性大麻素相关分子。
Liver Int. 2010 Jul;30(6):816-25. doi: 10.1111/j.1478-3231.2009.02137.x. Epub 2009 Oct 14.
5
Transcriptional mechanisms of WNT5A based on NF-kappaB, Hedgehog, TGFbeta, and Notch signaling cascades.基于核因子κB、刺猬信号通路、转化生长因子β和Notch信号级联的WNT5A转录机制
Int J Mol Med. 2009 Jun;23(6):763-9. doi: 10.3892/ijmm_00000190.
6
Essential role of Notch signaling in apoptosis of human pancreatic tumoral cells mediated by exosomal nanoparticles.Notch信号通路在由外泌体纳米颗粒介导的人胰腺肿瘤细胞凋亡中的重要作用。
Int J Cancer. 2009 Sep 1;125(5):1016-26. doi: 10.1002/ijc.24375.
7
The role of the endocannabinoid system in liver diseases.内源性大麻素系统在肝脏疾病中的作用。
Best Pract Res Clin Endocrinol Metab. 2009 Feb;23(1):65-77. doi: 10.1016/j.beem.2008.10.009.
8
Apoptosis induced in HepG2 cells by the synthetic cannabinoid WIN: involvement of the transcription factor PPARgamma.合成大麻素WIN诱导HepG2细胞凋亡：转录因子PPARγ的作用
Biochimie. 2009 Apr;91(4):457-65. doi: 10.1016/j.biochi.2008.11.003. Epub 2008 Nov 27.
9
The endocannabinoid anandamide inhibits cholangiocarcinoma growth via activation of the noncanonical Wnt signaling pathway.内源性大麻素花生四烯乙醇胺通过激活非经典Wnt信号通路抑制胆管癌生长。
Am J Physiol Gastrointest Liver Physiol. 2008 Dec;295(6):G1150-8. doi: 10.1152/ajpgi.90455.2008. Epub 2008 Oct 2.
10
Endocannabinoids in liver disease and hepatic encephalopathy.内源性大麻素与肝脏疾病和肝性脑病
Curr Pharm Des. 2008;14(23):2362-9. doi: 10.2174/138161208785740063.
Zotero 插件